A Phase I, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Five Daily Intravenous Infusions Repeated Every 28 Days in Adult Patients With Solid Tumors and Lymphomas
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2008
At a glance
- Drugs Iboctadekin (Primary)
- Indications Follicular lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Sep 2005 New trial record.